Full Press Release Details
SAN DIEGO, Nov. 11, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in November and December 2026.
Details of the conferences appear below:
Conference: 2026 Jefferies Global Healthcare Conference in London Date: Tuesday, November 17 and Wednesday, November 18, 2026 Location: London, UK Format: 1x1 Investor Meetings
Conference: Piper Sandler 38th Annual Healthcare Conference Date: Thursday, December 3, 2026 Time: 2:00pm ET Location: New York, NY Format: Fireside Chat Speaker: Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer
In addition to the fireside chat, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the Piper conference. A webcast of the Piper event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
| Contact: |
| Ashlee Dunston |
| Investor Relations and Public Affairs |
| adunston@atyrpharma.com |